Top-Rated Stocks NASDAQ:BCYC Bicycle Therapeutics - BCYC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $28.50 -0.37 (-1.28%) (As of 02/8/2023 05:18 PM ET) Add Compare Share Share Today's Range$28.10▼$29.5050-Day Range$26.93▼$32.9052-Week Range$12.08▼$51.93Volume142,888 shsAverage Volume229,265 shsMarket Capitalization$846.17 millionP/E RatioN/ADividend YieldN/APrice Target$52.64 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bicycle Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside84.7% Upside$52.64 Price TargetShort InterestHealthy6.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 25 Articles This WeekInsider TradingSelling Shares$279,441 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.84) to ($4.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector529th out of 1,026 stocksPharmaceutical Preparations Industry251st out of 504 stocks 3.4 Analyst's Opinion Consensus RatingBicycle Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.64, Bicycle Therapeutics has a forecasted upside of 84.7% from its current price of $28.50.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.30% of the outstanding shares of Bicycle Therapeutics have been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 5.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCYC. Previous Next 2.5 News and Social Media Coverage News SentimentBicycle Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Bicycle Therapeutics this week, compared to 5 articles on an average week.Search Interest9 people have searched for BCYC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 4 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $279,441.00 in company stock.Percentage Held by InsidersOnly 9.00% of the stock of Bicycle Therapeutics is held by insiders.Percentage Held by Institutions77.88% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.84) to ($4.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -8.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -8.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bicycle Therapeutics (NASDAQ:BCYC) StockBicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.Read More Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Stock News HeadlinesFebruary 8, 2023 | marketwatch.comBicycle Lock Market Growth Insights 2023: Industry Size and Share Analysis by Top Regions, Changing Technologies, and Opportunities Forecast to 2030February 8, 2023 | marketwatch.comBicycle Crankset Market can Sustain the Growth in Upcoming Years by 2023-2025 | Research Reports WorldFebruary 8, 2023 | Vantage Point (Ad)Predict These Market Breakouts with A.I.We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. February 8, 2023 | finance.yahoo.comBicycle Therapeutics to Participate in the SVB Securities Global Biopharma ConferenceFebruary 8, 2023 | marketwatch.comBicycle Wheels Market Forecast (2023-2029) Top Manufacturers - Shimano, Campagnolo, Fulcrum Wheels Srl, ENVEFebruary 7, 2023 | marketwatch.comCarbon Fiber Bicycle Market - 2023 [Latest Report] | Industry Set to Grow at a Remarkable Pace in Upcoming Years | Forecast till 2026February 7, 2023 | marketwatch.comSports Bicycle Market 2023 Size with Business Forecast up to 2027 & In-Depth Analysis in LATEST REPORTFebruary 7, 2023 | marketwatch.comBicycle Derailleur Market Size in 2023 Overview to New Players, Trends, Benefits & Opportunities till 2028February 8, 2023 | Vantage Point (Ad)Predict These Market Breakouts with A.I.We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. February 7, 2023 | marketwatch.comBicycle Apparels Market research report will demonstrate significant growth rates by 2028February 7, 2023 | marketwatch.comTwo-Wheel Bicycle Trailer Market 2023-2028 [New Report]: A Strong Foundation Post Covid-19 Sets the Stage for Continued OutperformanceFebruary 7, 2023 | marketwatch.comBicycle Gloves Market to Grow Exponentially Due to Rising DemandFebruary 7, 2023 | marketwatch.comBicycle Pedal Market Growth Developments 2023 with Key Suppliers, Industrial Applications, Emerging Supply-Demand and Forecast to 2028February 7, 2023 | marketwatch.comShared Bicycle Service Market International Business Analysis, Top Winning Strategies, Development Outlook and Regional Strategies 2029February 6, 2023 | marketwatch.comE-Bicycle Hub Motors Market Share Likely to Grow At a Impressive CAGRFebruary 6, 2023 | marketwatch.comBicycle Crankset Market Size, Share Global Industry, Future Trends, Growth Key Factors, Demand 2028February 6, 2023 | marketwatch.comCarbon Fiber Bicycle Frame Market is set to see Revolutionary growth in decadeFebruary 6, 2023 | marketwatch.comBicycle Bar End Market by Type, by Technology, by End User: Global Opportunity Analysis and Industry Forecast, 2023-2028February 6, 2023 | marketwatch.comBicycle Helmet Market Size 2023-2028 With Strategic Choice-Making Process, Identification of Main CorporationsFebruary 4, 2023 | americanbankingnews.comBrokerages Set Bicycle Therapeutics plc (NASDAQ:BCYC) PT at $49.90February 3, 2023 | marketwatch.comBicycle Parts and Components for Aftermarket Market 2023: Growth Outlook and Forecast 2027 with Top Leaders, Size and Share AnalysisFebruary 3, 2023 | marketwatch.comMid-Drive Electric Bicycle Market Size by Increasing Growth Rate, Business Analysis, and Trends Forecast to 2028February 3, 2023 | marketwatch.comBicycle Suspension System Market 2023 : Development, Growth, Key Factors And Forecast To 2029February 2, 2023 | marketwatch.comGlobal Bicycle Locks Market Growth (Size and Outlook) 2023 Research Report by Product Portfolios, Specifications and Forecast to 2029February 2, 2023 | marketwatch.comBicycle Rear Shocks Market 2023 : Size (value & volume) by Company, Key Regions, Type, and Application 2029February 2, 2023 | marketwatch.comBicycle Pumps Market 2023: Analysis Report with Historic and Upcoming Business Growth Revenue with Regional Segmentation Forecast to 2027February 1, 2023 | marketwatch.comGlobal Road Bicycle Market [2023-2026] | Latest Statistical Report with Tables and Graph to Get Control on Industry | Top Countries DataSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Company Calendar Last Earnings11/03/2021Today2/08/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCYC CUSIPN/A CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees119Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.64 High Stock Price Forecast$80.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+84.7%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,820,000.00 Net Margins-669.65% Pretax Margin-681.96% Return on Equity-31.56% Return on Assets-22.37% Debt Debt-to-Equity Ratio0.10 Current Ratio9.18 Quick Ratio9.18 Sales & Book Value Annual Sales$11.70 million Price / Sales72.32 Cash FlowN/A Price / Cash FlowN/A Book Value$11.78 per share Price / Book2.42Miscellaneous Outstanding Shares29,690,000Free Float27,017,000Market Cap$846.17 million OptionableNot Optionable Beta0.72 Key ExecutivesKevin LeeChief Executive Officer & Executive DirectorLee H. KalowskiPresident & Chief Financial OfficerAlistair MilnesChief Operating OfficerMichael SkynnerChief Technology OfficerNicholas KeenChief Scientific OfficerKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTJanux TherapeuticsNASDAQ:JANXPharming GroupNASDAQ:PHARMirum PharmaceuticalsNASDAQ:MIRMInnovivaNASDAQ:INVAView All CompetitorsInsiders & InstitutionsHandelsbanken Fonder ABBought 1,800 shares on 2/7/2023Ownership: 0.444%TD Asset Management IncBought 8,000 shares on 2/7/2023Ownership: 0.079%Cutler Group LLC CABought 800 shares on 2/7/2023Ownership: 0.000%AtonRa PartnersSold 4,527 shares on 2/2/2023Ownership: 0.057%Simplex Trading LLCBought 13,100 shares on 2/2/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions BCYC Stock - Frequently Asked Questions Should I buy or sell Bicycle Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCYC shares. View BCYC analyst ratings or view top-rated stocks. What is Bicycle Therapeutics' stock price forecast for 2023? 13 brokerages have issued 12 month price targets for Bicycle Therapeutics' stock. Their BCYC share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's stock price to reach $52.64 in the next year. This suggests a possible upside of 82.6% from the stock's current price. View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts. How have BCYC shares performed in 2023? Bicycle Therapeutics' stock was trading at $29.60 at the start of the year. Since then, BCYC stock has decreased by 2.6% and is now trading at $28.82. View the best growth stocks for 2023 here. When is Bicycle Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our BCYC earnings forecast. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.02. The firm had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.29 million. Bicycle Therapeutics had a negative net margin of 669.65% and a negative trailing twelve-month return on equity of 31.56%. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC). When did Bicycle Therapeutics IPO? (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Bicycle Therapeutics' stock symbol? Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC." Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Handelsbanken Fonder AB (0.44%), Harbor Capital Advisors Inc. (0.08%), TD Asset Management Inc (0.08%), AtonRa Partners (0.06%), Simplex Trading LLC (0.00%) and Twelve Points Wealth Management LLC (0.02%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bicycle Therapeutics' stock price today? One share of BCYC stock can currently be purchased for approximately $28.82. How much money does Bicycle Therapeutics make? Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $855.67 million and generates $11.70 million in revenue each year. The company earns $-66,820,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis. How many employees does Bicycle Therapeutics have? The company employs 119 workers across the globe. How can I contact Bicycle Therapeutics? Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503. This page (NASDAQ:BCYC) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.